May 13, 2026 10:11 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Vijay-led TVK wins Tamil Nadu floor test as AIADMK split plays out | Congress veteran Sonia Gandhi admitted to Medanta Hospital in Gurugram | PM Modi halves convoy size after austerity call | Mulayam Singh's younger son Prateek Yadav dies at 38 | Protests erupt in Delhi after NEET UG 2026 cancellation over alleged paper leak | AIADMK cracks widen after Tamil Nadu defeat; faction backs Vijay-led TVK government | Himanta Biswa Sarma takes oath as Assam CM for second term after BJP’s landslide win | Bengali rights activist Garga Chatterjee arrested over alleged provocative remarks ahead of assembly polls | No return to full WFH yet: IT firms unlikely to change hybrid work model despite PM Modi’s appeal | Suvendu Adhikari Cabinet clears BSF land transfer, census rollout, Ayushman Bharat in Bengal
Japan I Covid19
Image Cr: Unsplash

Japan approves home-made Covid-19 cure for emergency use

| @indiablooms | Nov 24, 2022, at 06:44 pm

Tokyo/UNI: The Japanese Health Ministry has authorised the island nation's first locally made COVID-19 oral treatment, Xocova, for emergency use.

This emergency approval was granted on the anticipated efficacy of Xocova and the acceptability of its safety profile based on the results obtained through the Phase 2 part (497 cases including the Phase 2a and Phase 2b parts combined) and the Phase 3 part (1,821 cases) of the Phase 2/3 study.

The pill was developed by Osaka-based pharmaceutical firm Shionogi & Co to treat coronavirus patients after they develop initial symptoms, such as fever, cough, a sore throat, a runny nose, and fatigue.

Xocova is an oral antiviral agent administered once daily for five days that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

It has been proven the most effective when administered during the first three days of symptoms starting.

The drug is known to reduce the viral load to three percent when taken on day four, and is not recommended for use during pregnancy.

Shionogi had filed for manufacturing and sales approval on Feb. 25, 2020.

The company said it had enough pills to treat one million people, and the drug will hit the shelves in Dec.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.